Moberg Pharma reports losses for nine months
Statements (6)
- Bearish
Moberg Pharma reported a net loss of 1.7 million kronor after tax for the third quarter of 2026.
- Bearish
Moberg Pharma reported EBITDA of SEK -8.5 million for the period from January to September 2026.
- Bearish
Moberg Pharma reported diluted earnings per share of SEK -0.13 for the period from January to September 2026.
- Neutral
Moberg Pharma reported net revenue of SEK 16.5 million for the period from January to September 2026.
- Bearish
Moberg Pharma reported operating profit (EBIT) of SEK -9.8 million for the period from January to September 2026.
- Bearish
Moberg Pharma reported profit for the period of SEK -6.3 million for the period from January to September 2026.